UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
08 mai 2018 08h00 HE
|
UroGen Pharma Ltd.
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first...
UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
24 avr. 2018 08h00 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
03 avr. 2018 08h32 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
15 mars 2018 07h00 HE
|
UroGen Pharma Ltd.
Presentation of MitoGel™ Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting Conference Call to be Held Today at...
UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018
08 mars 2018 08h00 HE
|
UroGen Pharma Ltd.
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report fourth...
UroGen to Present at March 2018 Investor Conferences
07 mars 2018 08h00 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018: Cowen...
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
14 févr. 2018 08h00 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
23 janv. 2018 16h01 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
18 janv. 2018 19h10 HE
|
UroGen Pharma Ltd.
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
16 janv. 2018 16h05 HE
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...